Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Open Access
- 4 March 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (9), 1850-1857
- https://doi.org/10.1182/blood-2009-10-249128
Abstract
Therapy-related myelodysplastic syndromes (t-MDSs) and acute myeloid leukemia (t-AML) have a poor prognosis with conventional therapy. Encouraging results are reported after allogeneic transplantation. We analyzed outcomes in 868 persons with t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004. A myeloablative regimen was used for conditioning in 77%. Treatment-related mortality (TRM) and relapse were 41% (95% confidence interval [CI], 38-44) and 27% (24-30) at 1 year and 48% (44-51) and 31% (28-34) at 5 years, respectively. Disease-free (DFS) and overall survival (OS) were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively. In multivariate analysis, 4 risk factors had adverse impacts on DFS and OS: (1) age older than 35 years; (2) poor-risk cytogenetics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor. Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50% (95% CI, 38-61), 26% (20-31), 21% (16-26), 10% (5-15), and 4% (0-16), respectively (P < .001). These data permit a more precise prediction of outcome and identify subjects most likely to benefit from allogeneic transplantation.Keywords
This publication has 38 references indexed in Scilit:
- Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantationHaematologica, 2009
- Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict SurvivalTransplantation and Cellular Therapy, 2008
- Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic TransplantationTransplantation and Cellular Therapy, 2007
- Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Bone Marrow Transplantation, 2006
- Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphomaBone Marrow Transplantation, 2003
- Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control studyBlood, 2002
- Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignanciesBone Marrow Transplantation, 1999
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasiaBone Marrow Transplantation, 1997
- Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromesAmerican Journal of Hematology, 1991